ATE469908T1 - Verfahren zur herstellung von pimecrolimus - Google Patents

Verfahren zur herstellung von pimecrolimus

Info

Publication number: ATE469908T1
Authority: AT; Austria
Prior art keywords: pimecrolimus; producing; macrolides; tacrolimus; crystallization
Prior art date: 2004-12-01

Application number

AT05848723T

Other languages

English (en)

Inventor

Viktor Gyollai

Csaba Szabo

Original Assignee

Teva Gyogyszergyar Zartkoeruen

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-01

Filing date

2005-12-01

Publication date

2010-06-15

2005-12-01 Application filed by Teva Gyogyszergyar Zartkoeruen filed Critical Teva Gyogyszergyar Zartkoeruen

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE469908T1 publication Critical patent/ATE469908T1/de

Links

KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 title abstract 2
229960005330 pimecrolimus Drugs 0.000 title abstract 2
238000004519 manufacturing process Methods 0.000 title 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract 1
238000002425 crystallisation Methods 0.000 abstract 1
230000008025 crystallization Effects 0.000 abstract 1
239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
229940041033 macrolides Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229960001967 tacrolimus Drugs 0.000 abstract 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Biochemistry (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT05848723T 2004-12-01 2005-12-01 Verfahren zur herstellung von pimecrolimus ATE469908T1 (de)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US63237204P	2004-12-01	2004-12-01
US63392604P	2004-12-06	2004-12-06
US64169705P	2005-01-05	2005-01-05
US64186805P	2005-01-05	2005-01-05
US64186905P	2005-01-05	2005-01-05
US66244005P	2005-03-16	2005-03-16
US70568105P	2005-08-03	2005-08-03
US70916005P	2005-08-17	2005-08-17
PCT/US2005/043541 WO2006060614A1 (en)	2004-12-01	2005-12-01	Methods for preparing pimecrolimus

Publications (1)

Publication Number	Publication Date
ATE469908T1 true ATE469908T1 (de)	2010-06-15

Family

ID=36097009

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05848723T ATE469908T1 (de)	2004-12-01	2005-12-01	Verfahren zur herstellung von pimecrolimus

Country Status (11)

Country	Link
US (5)	US7589100B2 (de)
EP (4)	EP1817314A1 (de)
JP (4)	JP2007523069A (de)
KR (1)	KR20070060144A (de)
AT (1)	ATE469908T1 (de)
CA (4)	CA2584358A1 (de)
DE (1)	DE602005021684D1 (de)
IL (4)	IL182869A0 (de)
MX (2)	MX2007005221A (de)
TW (3)	TW200628483A (de)
WO (4)	WO2006060616A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6306166B1 (en) *	1997-08-13	2001-10-23	Scimed Life Systems, Inc.	Loading and release of water-insoluble drugs
ES2339682T3 (es) *	2004-06-01	2010-05-24	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Procedimiento para la preparacion de la forma amorfa de un farmaco.
WO2006060616A1 (en) *	2004-12-01	2006-06-08	Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg	Processes for producing crystalline macrolides
US7812032B2 (en)	2006-07-25	2010-10-12	Abbott Laboratories	Crystalline forms of rapamycin analogs
US7820812B2 (en)	2006-07-25	2010-10-26	Abbott Laboratories	Methods of manufacturing crystalline forms of rapamycin analogs
JP2010500286A (ja) *	2006-07-25	2010-01-07	アボット・ラボラトリーズ	結晶形態のラパマイシン類似体
WO2008057511A2 (en) *	2006-11-06	2008-05-15	Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
JP2010515753A (ja)	2007-01-10	2010-05-13	ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム	肺内送達用免疫抑制剤組成物の送達の増強
BRPI0823269B8 (pt)	2007-01-21	2021-06-22	Hemoteq Ag	cateter de balão
AU2008211950A1 (en) *	2007-01-29	2008-08-07	Eisai R & D Management Co., Ltd.	Solid of macrolide compound, method for production thereof, and pharmaceutical composition comprising the same
US9192697B2 (en)	2007-07-03	2015-11-24	Hemoteq Ag	Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
CL2008000374A1 (es) *	2008-02-05	2008-04-04	Igloo Zone Chile S A	Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
JP5643770B2 (ja) *	2009-01-21	2014-12-17	バイオコン・リミテッドＢｉｏｃｏｎＬｉｍｉｔｅｄ	シロリムスの安定性の決定方法およびその安定形態の調製方法
IT1394309B1 (it)	2009-05-22	2012-06-06	Poli Ind Chimica Spa	Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
US10369256B2 (en)	2009-07-10	2019-08-06	Boston Scientific Scimed, Inc.	Use of nanocrystals for drug delivery from a balloon
WO2011008393A2 (en)	2009-07-17	2011-01-20	Boston Scientific Scimed, Inc.	Nucleation of drug delivery balloons to provide improved crystal size and density
WO2011081712A1 (en) *	2009-12-31	2011-07-07	Boston Scientific Scimed, Inc.	Cryo activated drug delivery and cutting balloons
EP2554530B2 (de) *	2010-03-29	2019-06-12	Daikin Industries, Ltd.	Verfahren zur herstellung von 3-chlor-pentafluorpropen
WO2012011877A2 (en)	2010-07-23	2012-01-26	Curiox Biosystems Pte Ltd	Apparatus and method for multiple reactions in small volumes
WO2012017449A1 (en)	2010-08-04	2012-02-09	Meril Life Sciences Pvt. Ltd	Process for preparation of novel 42-0-(heteroalkoxyalkyl) rapamycin compounds with anti-proliferative properties"
WO2012031236A1 (en)	2010-09-02	2012-03-08	Boston Scientific Scimed, Inc.	Coating process for drug delivery balloons using heat-induced rewrap memory
US9327264B2 (en) *	2011-01-31	2016-05-03	Uchicago Argonne, Llc	Containerless synthesis of amorphous and nanophase organic materials
WO2013022458A1 (en)	2011-08-05	2013-02-14	Boston Scientific Scimed, Inc.	Methods of converting amorphous drug substance into crystalline form
WO2013028208A1 (en)	2011-08-25	2013-02-28	Boston Scientific Scimed, Inc.	Medical device with crystalline drug coating
EP2972258B1 (de)	2013-03-15	2021-08-04	Biosensors International Group, Ltd.	Reinigung von rapamycinderivaten
KR102495018B1 (ko)	2013-11-15	2023-02-06	아케비아 테라퓨틱스 인코포레이티드	｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
WO2016078481A1 (zh)	2014-11-21	2016-05-26	杭州领业医药科技有限公司	一种含他克莫司的药物组合物及其制备方法
EP3380174A4 (de) *	2015-11-28	2019-04-24	Biopreme Medical Technologies, Inc.	Unterdruckeinspritzvorrichtung
EP3178824A1 (de)	2015-12-08	2017-06-14	Medichem, S.A.	Verfahren zur herstellung von pimecrolimus
US10975097B2 (en)	2017-05-01	2021-04-13	Meda Ab	Process to convert technical ascomycin into purified pimecrolimus
CN108948046B (zh) *	2017-05-20	2020-11-10	鲁南制药集团股份有限公司	一种替西罗莫司的中间体及其制备方法
CN110540567B (zh) *	2018-05-28	2024-07-30	深圳市天维生物药业有限公司	一种天维菌素b的晶型及其制备方法和用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3244592A (en)	1962-06-09	1966-04-05	Arai Tadashi	Ascomycin and process for its production
US4894366A (en)	1984-12-03	1990-01-16	Fujisawa Pharmaceutical Company, Ltd.	Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
RO107257B1 (ro) *	1987-07-09	1993-10-30	Pfizer	Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
EP0323865A1 (de)	1988-01-07	1989-07-12	Merck & Co. Inc.	Immunopressantes Mittel
DE68925080T2 (de) *	1988-08-01	1996-05-15	Fujisawa Pharmaceutical Co	FR-901154- und FR-901155-Derivate, Verfahren zu ihrer Herstellung
NZ235991A (en) *	1989-11-09	1993-05-26	Sandoz Ltd	Macrolide compounds and pharmaceutical compositions thereof
EP0480623A1 (de)	1990-10-11	1992-04-15	Merck & Co. Inc.	Halomakrolide und Derivate mit immunosuppressiver Wirkung
WO1993004680A1 (en)	1991-09-05	1993-03-18	Abbott Laboratories	Macrocyclic immunomodulators
WO1993018050A1 (en)	1992-03-02	1993-09-16	Pfizer Inc.	Sugar derivatives of macrolides
US5359060A (en) *	1993-07-06	1994-10-25	Pfizer, Inc.	Phosponated derivatives of macrolides
UA41884C2 (uk) *	1993-11-05	2001-10-15	Амерікан Хоум Продактс Корпорейшн	Спосіб відокремлення рапаміцину від кислотних, основних та неполярних нейтральних домішок, присутніх в концентраті екстрактів ферментаційного бульйону або маточних розчинів
GB9618952D0 (en)	1996-09-11	1996-10-23	Sandoz Ltd	Process
GB9713730D0 (en) *	1997-06-30	1997-09-03	Ciba Geigy Ag	Organic compounds
KR100440553B1 (ko) *	1998-03-26	2004-07-15	후지사와 야꾸힝 고교 가부시키가이샤	서방성 제제
GB9904930D0 (en) *	1999-03-04	1999-04-28	Glaxo Group Ltd	Thiazoloindolinone compounds
DE60013434T2 (de)	1999-05-25	2005-01-20	Fujisawa Pharmaceutical Co., Ltd.	Verfahren zur trennung analoger organischer verbindungen
TW553946B (en)	1999-09-08	2003-09-21	Fujisawa Pharmaceutical Co	Method for separating lactone-containing high-molecular weight compounds
ES2177373B1 (es)	1999-11-26	2003-11-01	Astur Pharma Sa	Preparacion de azitromicina en su forma no cristalina
GB0012383D0 (en) *	2000-05-22	2000-07-12	Novartis Ag	Organic compounds
MXPA04007433A (es)	2002-02-01	2004-10-11	Pfizer Prod Inc	Procedimiento para preparar dispersiones solidas amorfas homogeneas de farmaco secadas por pulverizacion utilizando un dispositivo de secado por pulverizacion modificado.
PL371593A1 (en)	2002-02-01	2005-06-27	Pfizer Products Inc.	Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
KR20040086369A (ko) *	2002-02-13	2004-10-08	비오갈 기오기스제르갸르 알티.	바이오매터로부터 마크롤라이드를 추출하는 방법
JP4298212B2 (ja) *	2002-03-29	2009-07-15	大日本印刷株式会社	塩酸エピナスチン高融点型結晶の製造法
EP1513847A2 (de)	2003-03-31	2005-03-16	Biogal Gyogyszergyar Rt.	Kristallisierung und aufreinigung von macroliden
US7220357B2 (en)	2003-07-24	2007-05-22	Teva Gyógyszergyár Zártkörúen Múkó´dó´Résvénytársaság	Method of purifying macrolides
AU2003269473A1 (en)	2003-08-26	2005-03-10	Biocon Limited	A process for the recovery of substantially pure tricyclic macrolide
ES2339682T3 (es) *	2004-06-01	2010-05-24	Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag	Procedimiento para la preparacion de la forma amorfa de un farmaco.
CA2580123A1 (en) *	2004-09-10	2006-03-23	Ivax Pharmaceuticals S.R.O.	Process for isolation of macrolide compounds
KR20070057910A (ko) *	2004-09-10	2007-06-07	아이박스 파마슈티컬스 에스.알.오.	결정질 타크롤리무스의 분리 방법
GT200500282A (es) *	2004-10-12	2006-05-04		Heteroatomos conteniendo compuestos triciclicos.
WO2006060616A1 (en) *	2004-12-01	2006-06-08	Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg	Processes for producing crystalline macrolides

2005
- 2005-12-01 WO PCT/US2005/043543 patent/WO2006060616A1/en not_active Ceased
- 2005-12-01 CA CA002584358A patent/CA2584358A1/en not_active Abandoned
- 2005-12-01 JP JP2006551653A patent/JP2007523069A/ja active Pending
- 2005-12-01 WO PCT/US2005/043541 patent/WO2006060614A1/en not_active Ceased
- 2005-12-01 MX MX2007005221A patent/MX2007005221A/es unknown
- 2005-12-01 AT AT05848723T patent/ATE469908T1/de not_active IP Right Cessation
- 2005-12-01 JP JP2006551655A patent/JP2007523896A/ja active Pending
- 2005-12-01 US US11/293,283 patent/US7589100B2/en not_active Expired - Fee Related
- 2005-12-01 EP EP05826343A patent/EP1817314A1/de not_active Withdrawn
- 2005-12-01 US US11/293,286 patent/US7439252B2/en not_active Expired - Fee Related
- 2005-12-01 CA CA002584365A patent/CA2584365A1/en not_active Abandoned
- 2005-12-01 TW TW094142326A patent/TW200628483A/zh unknown
- 2005-12-01 TW TW094142290A patent/TWI315310B/zh not_active IP Right Cessation
- 2005-12-01 US US11/293,747 patent/US7645876B2/en not_active Expired - Fee Related
- 2005-12-01 TW TW094142291A patent/TW200631955A/zh unknown
- 2005-12-01 EP EP05848573A patent/EP1817315A1/de not_active Withdrawn
- 2005-12-01 WO PCT/US2005/043544 patent/WO2006060617A1/en not_active Ceased
- 2005-12-01 US US11/293,353 patent/US7279571B2/en not_active Expired - Fee Related
- 2005-12-01 KR KR1020077010037A patent/KR20070060144A/ko not_active Ceased
- 2005-12-01 EP EP05848588A patent/EP1817316A1/de not_active Withdrawn
- 2005-12-01 CA CA002584430A patent/CA2584430A1/en not_active Abandoned
- 2005-12-01 DE DE602005021684T patent/DE602005021684D1/de not_active Expired - Lifetime
- 2005-12-01 WO PCT/US2005/043542 patent/WO2006060615A1/en not_active Ceased
- 2005-12-01 CA CA002584360A patent/CA2584360A1/en not_active Abandoned
- 2005-12-01 EP EP05848723A patent/EP1817317B1/de not_active Expired - Lifetime
- 2005-12-01 MX MX2007005222A patent/MX2007005222A/es unknown
- 2005-12-01 JP JP2006551654A patent/JP2007519758A/ja active Pending
- 2005-12-01 JP JP2006551652A patent/JP2007519757A/ja active Pending
2007
- 2007-04-30 IL IL182869A patent/IL182869A0/en unknown
- 2007-04-30 IL IL182871A patent/IL182871A0/en unknown
- 2007-04-30 IL IL182872A patent/IL182872A0/en unknown
- 2007-04-30 IL IL182870A patent/IL182870A0/en unknown
- 2007-07-24 US US11/881,033 patent/US20070270451A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US7279571B2 (en)	2007-10-09
KR20070060144A (ko)	2007-06-12
US20070270451A1 (en)	2007-11-22
US7645876B2 (en)	2010-01-12
US7439252B2 (en)	2008-10-21
MX2007005221A (es)	2007-06-22
JP2007523896A (ja)	2007-08-23
EP1817317A1 (de)	2007-08-15
DE602005021684D1 (de)	2010-07-15
US20060155119A1 (en)	2006-07-13
CA2584365A1 (en)	2006-06-08
EP1817314A1 (de)	2007-08-15
US20060135548A1 (en)	2006-06-22
CA2584430A1 (en)	2006-06-08
CA2584360A1 (en)	2006-06-08
TWI315310B (en)	2009-10-01
EP1817315A1 (de)	2007-08-15
CA2584358A1 (en)	2006-06-08
TW200626604A (en)	2006-08-01
JP2007523069A (ja)	2007-08-16
US20060147540A1 (en)	2006-07-06
IL182872A0 (en)	2007-08-19
US20060142564A1 (en)	2006-06-29
EP1817317B1 (de)	2010-06-02
WO2006060616A1 (en)	2006-06-08
EP1817316A1 (de)	2007-08-15
IL182871A0 (en)	2007-08-19
TW200628483A (en)	2006-08-16
IL182870A0 (en)	2007-08-19
IL182869A0 (en)	2007-08-19
TW200631955A (en)	2006-09-16
WO2006060615A1 (en)	2006-06-08
MX2007005222A (es)	2007-06-26
JP2007519758A (ja)	2007-07-19
US7589100B2 (en)	2009-09-15
JP2007519757A (ja)	2007-07-19
WO2006060614A1 (en)	2006-06-08
WO2006060614A9 (en)	2006-08-31
WO2006060617A1 (en)	2006-06-08

Legal Events

Date	Code	Title	Description
2010-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE469908T1 (de)	2010-06-15	Verfahren zur herstellung von pimecrolimus
ATE510838T1 (de)	2011-06-15	Verfahren zur herstellung von 2-methyl-1-(2- methylpropyl)-1h-imidazoä4,5-cüä1,5ünaphthyridi - 4-amin
DE502006000218D1 (de)	2008-01-24	Verfahren zur Herstellung von SiOC-verknüpften, linearen Polydialkylsiloxan-Polyoxyalkylen-Blockcopolymeren
DE60333149D1 (de)	2010-08-12	Verfahren zur Herstellung von organischen elektrolumineszenten Vorrichtungen
ATE435209T1 (de)	2009-07-15	Verfahren zur herstellung von montelukast-natrium
ATE408609T1 (de)	2008-10-15	Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE440888T1 (de)	2009-09-15	Verfahren zur herstellung von glatiramer
DE602005026987D1 (de)	2011-04-28	Verfahren zur herstellung von 1,2-dichlorethan
ATE482966T1 (de)	2010-10-15	Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
ATE529395T1 (de)	2011-11-15	Verfahren zur herstellung von organischen carbonaten
ATE453603T1 (de)	2010-01-15	Integriertes verfahren zur selektiven oxydation von organischen verbindungen
ATE546524T1 (de)	2012-03-15	Verfahren zur herstellung aktiver scfv-antikörper und bibliotheken dafür
ATE486841T1 (de)	2010-11-15	Verfahren zur herstellung von pregabalin und salzen daraus
EP4432790A4 (de)	2025-07-23	Durchkontaktierungssubstrat, montagesubstrat und verfahren zur herstellung des durchkontaktierungssubstrats
ATE527012T1 (de)	2011-10-15	Verfahren zur herstellung von medizinprodukten mit einer opferstruktur
ATE516290T1 (de)	2011-07-15	Verfahren zur herstellung von buprenorphin und derivaten von buprenorphin
ATE455778T1 (de)	2010-02-15	Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
DE502006006803D1 (de)	2010-06-02	Verfahren zur herstellung von leder
EP1848843A4 (de)	2011-09-28	Verfahren zur herstellung von gerichtet erstarrten verfestigten siliciumstäben
ATE376997T1 (de)	2007-11-15	Verfahren zur herstellung von 1,4- diphenylazetidinon-derivaten
ATE402684T1 (de)	2008-08-15	Elastische befestigungslasche, befestigungssystem und verfahren zur herstellung davon
DE602005016095D1 (de)	2009-10-01	Verfahren zur herstellung von hochreinem teicoplanin
ATE466843T1 (de)	2010-05-15	Verfahren zur herstellung von n-piperidino-1,5- diphenylpyrazol-3-carboxamid-derivaten
DE602004014264D1 (de)	2008-07-17	Verfahren zur herstellung von olanzapin
ATE459610T1 (de)	2010-03-15	Verfahren zur herstellung von alkenylbernsteinsäureanhydriden